Neuroprotectors in the correction of cognitive impairment

doi:https://doi.org/10.17116/jnevro2018118091130

Close metadata

Recommended articles:

Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

Activation of endogenous mechanisms of sanogenesis in cognitive impairment in cerebral small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):7-13

Cognitive impairment in bilinguals with neurological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):26-29

Modern aspects of chronic cerebral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113

The relationship between neuropsychological indicators and neuroimaging changes according to MRI morphometry in patients with Alzheimer’s disease and glaucoma. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):142-152

Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16

The possibilities of Mexidol in the complex therapy of arterial hypertension. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):572-580

International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Russian Journal of Preventive Medicine. 2024;(10):72-83

Resolution of the expert council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders». Russian Journal of Preventive Medicine. 2024;(11):85-93

Differentiated approach to cognitive rehabilitation of patients after stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):5-11

Abstract:

The main groups of neuroprotectors, which are active in preventing the processes of the death of the nerve cells of vascular, traumatic, toxic and other etiologies and can decrease the severity of cognitive impairment, include phosphatidylcholine, phosphatidylserine, preparations based on ginkgo biloba, group B vitamins, folic acid. Preparations based on ginkgo biloba have the same effect as synthetic nootropics. The antioxidant and membrane-stabilizing effects of neuroprotectors are highlighted. In view of practical applications, attention is given to the advantages of the combinations of different neuroprotectors. Cerebrovin as one of these drugs can be recommended for treatment of cognitive impairment in the elderly.

Keywords:

cognitive impairment

phosphatidylcholine

ginkgo biloba

B vitamins

folic acid

Close metadata

References:

Plataras C, Taskiris S, Angelogianni P. Effect of CDP-choline on brain acetylcholinesterase and Na⁺/K⁺-ATPase in adult rats. Clin Biochem. 2000;33:351-357. https://doi.org/10.1016/s0009-9120(00)00084-9
Romanenko VI, Romanenko YuI, Romanenko IV. Polyunsaturated fatty acids in mild cognitive disorders. Mezhdunarodnyj Nevrologicheskij Zhurnal. 2015;2(72):135-138. On 30.06.18. https://www.mif-ua.com/archive/issue-34395/ (In Russ.)
Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, Kameyama M, Omae T, Fujishima M, Sakuma A. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke. 1988;19:211-216. https://doi.org/10.1161/01.str.19.2.211
Shavlovskaya OA. The assessment of the efficacy of citicoline in the early and recovery stages of stroke. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(6):93-97. (In Russ.) https://doi.org/10.17116/jnevro20161166193-97
Zamroziewicz MK, Zwilling CE, Barbey AK. Inferior prefrontal cortex mediates the relationship between phosphatidylcholine and executive functions in healthy, older adults. Front Aging Neurosci. 2016;8:226. https://doi.org/10.3389/fnagi.2016.00226
Klavins K, Koal T, Dallmann G, Marksteiner J, Kemmler G, Humpel C. The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer’s disease and mild cognitive impairment. Alzheimers Dement (Amst). 2015;1(3):295-302. https://doi.org/10.1016/j.dadm.2015.05.003
Katunina EA. Ginkgo biloba: the results of half a century of experience. The polymodality of the effects of Ginkgo biloba: an experimental and clinical studies Consilium medicum. Nevrologiya i Revmatologiya. 2013;2:53-57. On 30.06.18. https://con-med.ru (In Russ.)
Levin OS. Primenenie ekstrakta Ginkgo biloba (EGb 761) dlya lecheniya kognitivnykh narushenii pri distsirkulyatornoi entsefalopatii. RMZh. 2009;17(20):1356-1361. Levin OS. Application of Ginkgo biloba extract (EGb 761) for the treatment of cognitive impairment in dyscirculatory encephalopathy. RMJ. 2009;17(20):1356-1361. On 30.06.18. https://www.rmj.ru (In Russ.)].
Ahlemeyer B, Krieglstein J. Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer’s disease. Pharmacopsych. 2003;36(1):8-14. https://doi.org/10.1055/s-2003-40454
Bridi R, Crossetti FP, Steffen VM, Henriques AT. The antioxidant activity of extract Ginkgo biloba EGb761 in rats. Phytother Res. 2001;15:449-451. https://doi.org/10.1002/ptr.814
Eckert A, Keil U, Kressmann S, Schindowski K , Leutner S, Leutz S, Müller WE. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsych. 2003;36(1):15-23. https://doi.org/10.1055/s-2003-40449
Gschwind YJ, Bridenbaugh SA, Reinhard S, Granacher U, Monsch AU, Kressig RW. Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study. Aging Clin Exp Res. 2017;29(4):609-619. https://doi.org/10.1007/s40520-016-0699-y
Palta P, Carlson MC, Crum RM, Colantuoni E, Sharrett AR, Yasar S, Nahin RL, DeKosky ST, Snitz B, Lopez O, Williamson JD, Furberg CD, Rapp SR, Golden SH. Diabetes and cognitive decline in older adults: the Ginkgo Evaluation of Memory study. J Gerontol A Biol Sci Med Sci. 2017;73(1):123-130. https://doi.org/10.1093/gerona/glx076
DeKosky ST, Fitzpatrick A, Ives DG, Saxton J, Williamson J, Lopez OL, Burke G, Fried L, Lewis H. Kuller, Robbins J, Tracy R, Woolard N, Dunn L, Kronmal R, Nahin R, Furberg C. The Ginkgo Evaluation of Memory (GEM) study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemporary Clinical Trials. 2006:27(3):238-253. https://doi.org/10.1016/j.cct.2006.02.007
Shavlovskaya OA. Treatment of asthenia and associated conditions with vitamin and mineral supplements. Medicinskij Sovet. 2015;17:55-61. (In Russ.) https://doi.org/10.21518/2079-701X-2015-17-55-61
Cho HS, Huang LK, Lee YT, Chan L, Hong CT. Suboptimal baseline serum vitamin B12 is associated with cognitive decline in people with Alzheimer’s disease undergoing cholinesterase inhibitor treatment. Front Neurol. 2018;9:325. https://doi.org/10.3389/fneur.2018.00325
Kamchatnov PR, Abusuyeva BA. B Vitamins in neurological practice. Effektivnaya Farmakoterapiya. 2014;5(49):52-58. On 30.06.18. (In Russ.) http://umedp.ru/magazines
Moore EM, Mander A, Ames D, Carne R, Sanders K, Watters D. Cognitive impairment and vitamin B12: a review. Int Psychogeriatr. 2012;24(4):541-556. https://doi.org/10.1017/s1041610211002511
Durga J, van Boxtel MPJ, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P. Effect of 3 year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007 Jan 20;369(9557):208-216. https://doi.org/10.1016/s0140-6736(07)60109-3
Ma F, Li Q, Zhou X, Zhao J, Song A, Li W, Liu H, Xu W, Huang G. Effects of folic acid supplementation on cognitive function and Aβ-related biomarkers in mild cognitive impairment: a randomized controlled trail. Eur J Nutr. 2017;2:1-12. https://doi.org/10.1007/s00394-017-1598-5
McGarel C, Pentieva K, Strain JJ, McNulty H. Emerging roles for folate and related B-vitamins in brain health across the lifecycle. Proc Nutr Soc. 2015;74(1):46-55. https://doi.org/10.1017/s0029665114001554